BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 75,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/ and Twitter @BDandCo.
BD Partners with IBMS to Release Advancing Cervical Cancer Screening Report
Addressing an urgent need to improve cervical cancer screening for all women and people with a cervix in the UK.
BD, in collaboration with the Institute of Biomedical Science (IBMS), announced the release of a pivotal healthcare report to address an urgent need to improve cervical cancer screening for all women and people with a cervix in the UK.
The report, Advancing Cervical Cancer Screening: Integrating Self-Sampling and Innovative Technologies for Equitable Access is the result of an in-depth roundtable discussion at IBMS with leading experts and commissioners in healthcare in response to disparities in cervical cancer screening.
The report identifies significant barriers to cervical cancer screening, especially among underserved communities, and calls for innovative strategies to enhance screening rates and outcomes for high-risk populations. It advocates for integrating self-sampling into healthcare systems to improve accessibility and recommends designing programs that address socioeconomic barriers and prioritize high-risk individuals.
The findings also highlight the need for careful planning in laboratory preparedness, kit distribution, and data collection, and points out that the benefits of self-sampling extend beyond cervical cancer to other HPV-related diseases and set out strategies to address disparities, enhance cervical cancer screening and improve health outcomes.
David Wells, Chief Executive of IBMS, commented: “This report represents a crucial step towards equitable cervical cancer prevention. By adopting the outlined recommendations, we can harness the power of self-sampling technologies to increase screening accessibility and improve health outcomes for all.”
Dr. Jeff Andrews, Vice President of Medical Affairs for Diagnostic Solutions at BD, commented: “Our collaboration with IBMS underscores the importance of self-collection for HPV screening, helping to overcome barriers and reach those previously under screened. Integrating self-collection with extended HPV genotype testing allows for precise risk assessment and targeted treatment, improving outcomes for those at higher risk.”
By embracing these innovations and prioritising high-risk populations, cervical cancer screening programs can be significantly improved which will help eliminate the cervical cancer disparities.
Full details on the report are available here.
About IBMS: The Institute of Biomedical Science (IBMS) is the professional body for biomedical scientists in the United Kingdom. For more information, visit www.ibms.org.
